Money Moves with Neil Devani

There are pockets of genuinely useful insight - the CGM market structure, the Eclipse incubation model (pre-identifying design partners before funding), and the strategic-acquirer identification process - but large portions of the 53 minutes are consumed by origin-story narrative, a tennis racket stringing anecdote, a medical-school detour, and a lightning round, sharply diluting the useful idea-per-minute rate.

“the vast majority of diabetics are managing their conditions with exercise, with diet, and potentially with an oral medication. And so 90% of the population is doing it that way. And they don't have a tool that's easy to use enough”

“most of the time we can right before we've even launched and funded the company, we've pressure tested the idea enough, identified a design partner or two or three and inked some of that right before the entrepreneur has gone on their journey”

The framing of 'high slope founder + high slope industry' is a mildly fresh articulation of a common VC heuristic, and the point that investors need founders more than founders need investors is a useful reframe, but there is no truly contrarian or first-principles argument across the episode - the fundraising advice, the exit narrative, and the incubation pitch all stay well within conventional startup discourse.

“the hard ones to say yes to. But perhaps the ones that are maybe you'll be rewarded. The boast for is taking a chance on someone that, that has promise and a high slope and an industry that also has a high slope”

“they need you way more than, than, than you do. Right? Uh, like you are, you are the asset that will get them the returns. If you win, they win and you win even more frankly than they do”

Ashwin is a genuine practitioner - eight years co-founding a medical device company, ~$40M raised, a real exit to One Drop, and now investing at Eclipse, a credible $5B AUM firm - but the exit was pre-revenue and relatively modest, and by his own admission he is a first-time investor, limiting the depth of hard-won operating and investing pattern recognition on display.

“from founding in 2012 to ultimately exiting in early 2020. It was like a eight year journey, most of which was us in the lab and in a manufacturing facility”

“In total, it was close to 40 million.”

The episode scores meaningfully on specificity in places - out-of-pocket CGM costs, investor count, named acquirer, named firms, and a vivid live-demo anecdote with a two-point accuracy match - but the exit terms and valuation are entirely absent, portfolio outcomes are described only directionally, and the incubation model's claimed speed advantages are asserted without data.

“continuous glucose monitors at that time would cost a patient out of pocket north of 6,000, $7,000 per year”

“we went and talked to I think it was 75 or 80 investors and I think N minus one of those said no”

The host occasionally surfaces a good follow-up ('What do you think got that one over the line?', 'Did it get easier over time?') and creates some useful pressure on the fundraising arc, but he never challenges exit economics, fund-level return claims, or the incubation model's actual results, and the back half of the episode drifts into a meandering personal-finance segment and a purely soft lightning round.

“What do you think got that one over the line?”

“What, what did you find in the subsequent rounds? Did it get easier over time now that you had a, uh, basic goal that you knew you had raised some money?”